In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $61.31 in the prior trading day, Biomarin Pharmaceutical Inc (NASDAQ: BMRN) closed at $60.35, down -1.57%. In other words, the price has decreased by -$1.57 from its previous closing price. On the day, 2.14 million shares were traded. BMRN stock price reached its highest trading level at $61.25 during the session, while it also had its lowest trading level at $59.8.
Ratios:
Our goal is to gain a better understanding of BMRN by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.85 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.93. For the most recent quarter (mrq), Quick Ratio is recorded 3.10 and its Current Ratio is at 4.83. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
On November 06, 2025, Stifel Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $61.
On September 08, 2025, H.C. Wainwright started tracking the stock assigning a Neutral rating and target price of $60.H.C. Wainwright initiated its Neutral rating on September 08, 2025, with a $60 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 20 ’25 when Burkhart Erin sold 1,786 shares for $59.31 per share. The transaction valued at 105,928 led to the insider holds 14,173 shares of the business.
Burkhart Erin bought 1,786 shares of BMRN for $105,928 on May 20 ’25. On May 02 ’25, another insider, Hubbard Cristin, who serves as the EVP, Chief Commercial Officer of the company, sold 273 shares for $64.92 each. As a result, the insider received 17,723 and left with 32,700 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMRN now has a Market Capitalization of 11594099712 and an Enterprise Value of 10720502784. As of this moment, Biomarin’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.61, and their Forward P/E ratio for the next fiscal year is 13.38. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.37. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.76 while its Price-to-Book (P/B) ratio in mrq is 1.91. Its current Enterprise Value per Revenue stands at 3.465 whereas that against EBITDA is 13.501.
Stock Price History:
The Beta on a monthly basis for BMRN is 0.26, which has changed by -0.0900861 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, BMRN has reached a high of $73.51, while it has fallen to a 52-week low of $50.76. The 50-Day Moving Average of the stock is 9.29%, while the 200-Day Moving Average is calculated to be 5.38%.
Shares Statistics:
The stock has traded on average 2.92M shares per day over the past 3-months and 1892780 shares per day over the last 10 days, according to various share statistics. A total of 192.10M shares are outstanding, with a floating share count of 190.03M. Insiders hold about 1.09% of the company’s shares, while institutions hold 96.80% stake in the company. Shares short for BMRN as of 1765756800 were 8099003 with a Short Ratio of 2.78, compared to 1763078400 on 8949150. Therefore, it implies a Short% of Shares Outstanding of 8099003 and a Short% of Float of 5.4.
Earnings Estimates
At present, 18.0 analysts are actively evaluating the performance of Biomarin Pharmaceutical Inc (BMRN) in the stock market.The consensus estimate for the next quarter is $1.26, with high estimates of $1.42 and low estimates of $1.07.
Analysts are recommending an EPS of between $3.77 and $3.26 for the fiscal current year, implying an average EPS of $3.57. EPS for the following year is $5.31, with 15.0 analysts recommending between $6.09 and $4.67.
Revenue Estimates
21 analysts predict $822.41M in revenue. The current quarter. It ranges from a high estimate of $852M to a low estimate of $788M. As of . The current estimate, Biomarin Pharmaceutical Inc’s year-ago sales were $747.31MFor the next quarter, 21 analysts are estimating revenue of $819.96M. There is a high estimate of $867M for the next quarter, whereas the lowest estimate is $787M.
A total of 25 analysts have provided revenue estimates for BMRN’s current fiscal year. The highest revenue estimate was $3.2B, while the lowest revenue estimate was $3.13B, resulting in an average revenue estimate of $3.17B. In the same quarter a year ago, actual revenue was $2.85BBased on 19 analysts’ estimates, the company’s revenue will be $3.42B in the next fiscal year. The high estimate is $3.84B and the low estimate is $3.2B.
